IP Library Granted Patent US 11,647,923
Granted Patent B2
US 11,647,923 · App. 17/203,387 · Granted May 16, 2023

Tissue profile wellness monitor

Inventor: Marcelo M. Lamego (Cupertino, CA)
Assignee: Masimo Corporation
A61B5/14551A61B5/0295A61B5/02416A61B5/72A61B5/7275A61B5/742A61B5/7405A61B5/746A61B5/7475
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,647,923
App. No.
17/203,387
Granted
May 16, 2023
Kind
B2
Abstract

A tissue profile wellness monitor measures a physiological parameter, generates a tissue profile, defines limits and indicates when the tissue profile exceeds the defined limits. The physiological parameter is responsive to multiple wavelengths of optical radiation after attenuation by constituents of pulsatile blood flowing within a tissue site. The tissue profile is responsive to the physiological parameter. The limits are defined for at least a portion of the tissue profile.

Claims (41)

1. A physiological monitoring method comprising:

receiving, from a sensor comprising a light source that emits light into a tissue site of a patient and a detector that detects a plurality of wavelengths of the emitted light after attenuation by the tissue site, a signal indicative of the detected light at each of the plurality of wavelengths;

determining a tissue profile curve across each of the plurality of wavelengths based at least in part on the signal indicative of the detected light at each of the plurality of wavelengths, wherein the tissue profile curve comprises at least a first portion and a second portion;

analyzing a shape of the tissue profile curve relative to a predefined boundary curve to determine patient wellness, wherein the first portion is analyzed in comparison to a first portion of the predefined boundary curve, and the second portion is analyzed in comparison to a second portion of the predefined boundary curve; and

outputting an indication in response to determining the shape of the tissue profile curve exceeds the predefined boundary curve.

2. The method of claim 1 , wherein the indication comprises at least one of a display, an alarm, a diagnostic, or a control.

3. The method of claim 1 , wherein determining the tissue profile curve comprises, at least in part:

measuring, from the signal, values indicative of an amount of light attenuation for at least some of the plurality wavelengths;

defining, based on characteristics of the tissue site, additional values corresponding to at least a portion of a wavelength spectrum between the respective wavelengths associated with the at least some of the plurality of wavelengths; and

combining the measured values at each of the at least some of the plurality wavelengths with the additional values.

4. The method of claim 1 further comprising:

outputting a first signal indicative of patient normalcy when the tissue profile curve is within the predefined boundary curve and a rate of change of the tissue profile curve is less than a maximum rate of change; and

outputting a second signal indicative of alert when at least a portion of the tissue profile curve is outside of the predefined boundary curve and the rate of change of the tissue profile curve is greater than the maximum rate of change.

5. The method of claim 1 , wherein the tissue profile curve is indicative of at least one of oxygen saturation of the patient, carboxyhemoglobin of the patient, or methemoglobin of the patient.

6. The method of claim 1 further comprising:

providing a first indication in response to the first and second portions not exceeding the respective first and second portions of the predefined boundary curve;

providing a second indication in response to one of the first or second portions exceeding the respective first or second portions of the predefined boundary curve; and

providing a third indication in response to both of the first and second portions exceeding the respective first and second portions of the predefined boundary curve.

7. The method of claim 1 , wherein determining the tissue profile curve comprises, at least in part:

determining, at each of the plurality of wavelengths and based on the signal, normalized plethysmographs (NPs); and

normalizing each of the determined NPs based on a reference wavelength.

8. The method of claim 7 , wherein the reference wavelength is one of the plurality of wavelengths.

9. A physiological monitoring method comprising:

receiving, from a sensor comprising a light source that emits light into a tissue site of a patient and a detector that detects a plurality of wavelengths of the emitted light after attenuation by the tissue site, a signal indicative of the detected light at each of the plurality of wavelengths;

determining a plurality of tissue profile curves over time and based at least in part on the signal indicative of the detected light at each of the plurality of wavelengths, wherein each of the tissue profile curves is across each of the plurality of wavelengths;

evaluating a trend in movement of the tissue profile curves over time relative to a predetermined trend limit to determine patient wellness; and

outputting an indication in response to determining the trend in movement of the tissue profile curves exceeds the predetermined trend limit.

10. The method of claim 9 , wherein the trend in movement of the tissue profile curve exceeding the predetermined trend limit indicates advance warning of deteriorating patient wellness.

11. The method of claim 9 , wherein determining the tissue profile curve comprises, at least in part:

determining, at each of the plurality of wavelengths and based on the signal, normalized plethysmographs (NPs); and

normalizing each of the determined NPs based on a reference wavelength.

12. The method of claim 11 , wherein the reference wavelength divides the tissue profile curve into a first portion and a second portion, and wherein the first portion is evaluated in relation to a first portion predetermined trend limit, and the second portion is evaluated in relation to a second portion predetermined trend limit.

13. The method of claim 12 further comprising:

providing a first indication in response to the first and second portions not exceeding the respective first and second portion predetermined trend limits;

providing a second indication in response to one of the first or second portions exceeding the respective first or second portion predetermined trend limits; and

providing a third indication in response to both of the first and second portions exceeding the respective first and second portion predetermined trend limits.

14. The method of claim 11 , wherein the reference wavelength is one of the plurality of wavelengths.

15. The method of claim 11 , wherein determining the tissue profile curve further comprises, at least in part:

defining continuous normalized NP values corresponding to at least a portion of a wavelength spectrum between the two or more of the plurality of wavelengths based at least in part on characteristics of the tissue site; and

combining the normalized NP values at each of the plurality of wavelengths with the defined continuous normalized NP values.

16. The method of claim 9 , wherein the tissue profile curve is indicative of at least one of oxygen saturation of the patient, carboxyhemoglobin of the patient, or methemoglobin of the patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2022
From: LAMEGO, MARCELO
To: MASIMO LABORATORIES, INC.
Reel/Frame 061158/0419 →
CHANGE OF NAME Recorded Sep 20, 2022
From: MASIMO LABORATORIES, INC.
To: CERCACOR LABORATORIES, INC.
Reel/Frame 061493/0775 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2022
From: CERCACOR LABORATORIES, INC.
To: MASIMO CORPORATION
Reel/Frame 061493/0827 →
Continuity (7)
Continuation 16286393 · Feb 26, 2019
Continuation 15814229 · Nov 15, 2017
Continuation 14599342 · Jan 16, 2015
Continuation 13764007 · Feb 11, 2013
Continuation 12106969 · Apr 21, 2008
Provisional Application 60925811 · Apr 21, 2007
Related Publication 20210204846A1 · Jul 8, 2021
Cited By (1)
US 12,329,548